C
Cathay Industrial Biotech
Chinese biotech company producing bio-based materials like long-chain dibasic acids and biopolyamides for sustainable plastics and textiles
About Cathay Industrial Biotech
Cathay Industrial Biotech operates as a publicly-traded company on the Shanghai Stock Exchange's STAR market, specializing in the research, development, production, and sale of bio-based materials through synthetic biology and bio-manufacturing. The company was founded in 2000 by Dr. Xiucai Liu, who serves as the Chairman and CEO. Dr. Liu's background includes a Ph.D. in Biochemistry from the University of Wisconsin-Milwaukee and postdoctoral positions at Yale and Columbia, providing a strong scientific foundation for the company's focus on industrial biotechnology. A key milestone was the company's IPO on the STAR market in August 2020.
The core of Cathay's business is the production of alternatives to petrochemical-based products, utilizing renewable resources like corn and other crop stalks. Revenue is generated through direct sales of its bio-based products and through strategic partnerships for technology and product development. The company's business model is vertically integrated, spanning from monomer production to polymer synthesis, serving a global client base that includes prominent companies like DuPont, Evonik, and Novo Nordisk. Cathay's primary offerings include a series of long-chain dicarboxylic acids (LCDAs), bio-based pentamethylene diamine (PDA), and bio-based polyamides. The company is a world-leading supplier of bio-manufactured LCDAs, which are used in applications such as nylons, resins, adhesives, and fragrances.
Cathay's main product lines are its bio-based monomers and its subsequent polyamide brands, TERRYL® for textiles and ECOPENT® for engineering applications. The bio-based polyamides (PA5X series) are created from the company's own bio-manufactured PDA and various diacids. These materials offer distinct properties such as inherent flame retardance, high toughness, and low moisture absorption, which stem from their odd-numbered carbon molecular structure. This positions them as sustainable alternatives in markets like automotive, electronics, textiles, and consumer goods, aiming to reduce carbon emissions compared to traditional petroleum-based nylons.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2020
- Outcome tier
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
News
Open roles
Cathay Industrial Biotech in the Huangpu ecosystem
The Cathay Industrial Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
BVCF
New Horizon Capital
Goldman Sachs
Series B and later1 investor entered at this stage
- SMShanxi Lu’an Mining
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
707 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cathay Industrial Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cathay Industrial Biotech on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

